0001140361-23-047679.txt : 20231011 0001140361-23-047679.hdr.sgml : 20231011 20231011080112 ACCESSION NUMBER: 0001140361-23-047679 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231011 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231011 DATE AS OF CHANGE: 20231011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FEMASYS INC CENTRAL INDEX KEY: 0001339005 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113713499 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40492 FILM NUMBER: 231319438 BUSINESS ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 770-500-3910 MAIL ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 8-K 1 ef20012287_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
October 11, 2023
 
Femasys Inc.
(Exact name of registrant as specified in its charter)
 

Delaware
001-40492
11-3713499
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

3950 Johns Creek Court, Suite 100
    
Suwanee, Georgia
  
30024
(Address of Principal Executive Offices)
  
(Zip Code)

(770) 500-3910
(Registrant’s telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per value
 FEMY
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b–2 of the Securities Exchange Act of 1934.

Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☒

Item 8.01.
Other Events.
 
On October 11, 2023, Femasys Inc. (the “Company”) announced that it had received a notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market, as the minimum bid price of the Company’s common stock had met or exceeded $1.00 per share for a minimum of ten consecutive business days.
 
The Company previously received a notice from Nasdaq on June 1, 2023 that the Company was not in compliance with the Rule, as the minimum bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on October 9, 2023, the tenth consecutive trading day when the closing bid price of the Company’s common stock was over $1.00. The notification of noncompliance had no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company had 180 calendar days, or until November 28, 2023, to regain compliance with the Rule.
 
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and incorporated into this Item 8.01 by reference.
 
Item 9.01.
Exhibits.
 
The following exhibits are filed as part of this report
 
Exhibit Number Description

 
Femasys Inc. Press Release dated October 11, 2023.
104
Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL).

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Femasys Inc.
     
Date: October 11, 2023
By:
/s/ Kathy Lee-Sepsick
   
Name: Kathy Lee-Sepsick
   
Title: Chief Executive Officer


EX-99.1 2 ef20012287_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
 
ATLANTA, October 11, 2023 -- Femasys Inc. (Nasdaq: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has it has received notice from The Nasdaq Stock Market LLC (Nasdaq) informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Consequently, Femasys is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market.
 
Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on October 9, 2023, the tenth consecutive trading day when the closing bid price of the Company’s common stock was over $1.00.
 
About Femasys
 
Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late-clinical stage product candidate and FDA-cleared, innovative therapeutic and diagnostic products. Femasys’ FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys’ FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared and has received regulatory approval in Canada. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada and other non-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The Company’s diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
 
Forward-Looking Statements 
 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. 

Contacts: 
 
Investors 
Chuck Padala 
LifeSci Advisors, LLC 
917-741-7792 
chuck@lifesciadvisors.com
 
Femasys Inc. 
Investor Contact: 
IR@femasys.com
 
Media Contact: 
Media@femasys.com

 
EX-101.SCH 3 femy-20231011.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 femy-20231011_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 femy-20231011_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 11, 2023
Entity File Number 001-40492
Entity Registrant Name Femasys Inc.
Entity Central Index Key 0001339005
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3713499
Entity Address, Address Line One 3950 Johns Creek Court
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Suwanee
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30024
City Area Code 770
Local Phone Number 500-3910
Title of 12(b) Security Common Stock, par value $0.001 per value
Trading Symbol FEMY
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 ef20012287_8k_htm.xml IDEA: XBRL DOCUMENT 0001339005 2023-10-11 2023-10-11 false 0001339005 8-K 2023-10-11 Femasys Inc. DE 001-40492 11-3713499 3950 Johns Creek Court Suite 100 Suwanee GA 30024 770 500-3910 false false false false Common Stock, par value $0.001 per value FEMY NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://femasys.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20012287_8k.htm femy-20231011.xsd femy-20231011_lab.xml femy-20231011_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20012287_8k.htm": { "nsprefix": "femy", "nsuri": "http://femasys.com/20231011", "dts": { "inline": { "local": [ "ef20012287_8k.htm" ] }, "schema": { "local": [ "femy-20231011.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "femy-20231011_lab.xml" ] }, "presentationLink": { "local": [ "femy-20231011_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://femasys.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231011to20231011", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20012287_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231011to20231011", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20012287_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001140361-23-047679-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-047679-xbrl.zip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